anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

224,881-224,940 of 319,975

filter-aware
20
The slide uses a before-and-after medical imaging comparison to demonstrate drug efficacy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The table tracks 3 patients across different cancer types, detailing their age, prior treatments, adverse events, dose-limiting toxicities (DLT), cycles completed, response, and current disposition.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
The slide uses a process flow diagram to map patient segments to specific dosing regimens and clinical goals.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
23
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
24
The slide uses a 2x2 grid of metrics to frame the problem/opportunity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
27
Includes specific adverse event data and clinical observations.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
28
Details specific patient enrollment numbers (~80 total, ~60 for primary analysis) and dosing randomization criteria.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
29
The slide uses a grid of metrics to define the addressable market and the clinical problem (progression after 1L).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
30
The slide presents clinical evidence linking AXL expression to poor patient outcomes in two different cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
31
The slide outlines a clinical trial protocol including patient disposition criteria and study endpoints.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
32
The table highlights the heavy pretreatment status of the patient population, specifically noting that a significant portion received 3 or more prior systemic therapies.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
33
Includes specific response rates, disease control rates, and confidence intervals for two patient cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
34
Waterfall plot shows best percentage change from baseline; spider plot shows change over time in weeks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
35
This is a classic swimmer plot used in oncology clinical trials to visualize time-on-treatment and response status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
36
Includes PET scan imagery comparing baseline to post-treatment status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
37
Data presented at IASLC 2023 North America Conference on Lung Cancer.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
38
Data cut date: 30Jun23. Includes events occurring in >=15% of patients or grade >=3 in >=3% of patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
41
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
42
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
43
Includes footnotes for data sources and a glossary of terms.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
44
The chart is a waterfall plot showing percentage change in tumor size. Red bars indicate partial response (PR).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
45
Uses a 2x2 grid layout to present key market metrics alongside current treatment efficacy benchmarks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
46
Includes specific patient counts and clinical outcomes (responses, stable disease, progressive disease).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
47
The slide uses a funnel-like logic to narrow down the addressable market from total prevalence to the 2L+ refractory segment.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
48
The slide uses a table to present clinical outcomes for specific cancer types, followed by a summary statement on the first-in-class status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
49
The table displays specific drug administration schedules for clinical evaluation.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
50
The table tracks specific dosing schedules (Q2W, 3Q4W, 2Q3W) and their progression status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
51
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
52
The slide uses a before-after-bridge style framing to contrast the problem (toxicity in standard bispecifics) with the solution (BA3182).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
53
The slide details the dose escalation strategy using accelerated, standard, and priming titration cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
54
The slide uses a simple 2-column table structure to represent a timeline.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Why Now1 hit
55
Uses a Venn-like diagram to connect technology, pipeline, and financial status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Why Now1 hit
01
Slide 1
BlackRock | Results Presentation Deck | 15 slidesBlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
02
The slide uses stacked bar charts to compare AUM vs Base Fees for four different business segmentations.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
03
Includes LTM organic asset growth rate and LTM organic base fee growth rate metrics.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What IsLoop · So What Cascade1 hit
04
Includes a detailed disclaimer regarding GAAP reconciliation and definition changes in Q1 2023.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What IsLoop · So What Cascade1 hit
05
The slide uses a combination of bar charts for repurchases and dividends, and a line chart for share count.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What IsLoop · So What Cascade1 hit
06
Includes a footnote regarding the calculation of the BLK Equity Index.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
07
The slide uses two waterfall charts to bridge revenue changes between periods.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
08
The slide uses two waterfall charts to show the bridge between different time periods.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · Before-AfterLoop · Before After1 hit
09
Includes a pie chart for expense composition, a table for percentage changes, and two waterfall charts for variance analysis.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · Before-AfterLoop · Before After1 hit
10
The waterfall chart shows the net change of $(14) million between 2022 and 2023.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · Revenue Buildup1 hit
11
The chart uses a break in the Y-axis for the 2022 and 2023 bars.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
12
The slide uses a waterfall bridge to explain the variance in expenses between two fiscal years.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
13
Includes a memo line for liquid credit and detailed definitions of asset categories.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
14
Includes detailed footnote regarding the 2023 update to non-GAAP definitions.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
15
This is a standard corporate legal disclosure slide.BlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations 1 hit
01
Slide 1
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations 1 hit
02
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations 1 hit
03
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Problem1 hit
04
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Problem1 hit
05
Includes a line chart showing Japanese visitor recovery relative to 2019 levels.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
06
The bar chart shows loan balances in billions, and the pie chart shows the percentage breakdown of the portfolio by loan type.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
Includes two pie charts showing loan composition by type and by impact status.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
Includes a list of key deposit metrics and characteristics.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
The chart illustrates the bank's ability to maintain lower deposit costs than peers during interest rate cycles.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit